Share on StockTwits

Relypsa (NASDAQ:RLYP) SVP Lance Berman sold 20,000 shares of the stock on the open market in a transaction dated Monday, August 25th. The shares were sold at an average price of $25.89, for a total value of $517,800.00. Following the transaction, the senior vice president now directly owns 7,500 shares of the company’s stock, valued at approximately $194,175. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Relypsa (NASDAQ:RLYP) traded up 0.11% during mid-day trading on Tuesday, hitting $26.52. The stock had a trading volume of 500,526 shares. Relypsa has a 52 week low of $11.55 and a 52 week high of $52.74. The stock has a 50-day moving average of $24.59 and a 200-day moving average of $28.0. The company’s market cap is $901.6 million.

Relypsa (NASDAQ:RLYP) last released its earnings data on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. On average, analysts predict that Relypsa will post $-2.47 earnings per share for the current fiscal year.

Separately, analysts at Stifel Nicolaus raised their price target on shares of Relypsa from $45.00 to $47.00 in a research note on Tuesday, August 12th. They now have a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $48.50.

Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.